Global Liver Cancer Drugs Market Analysis
The global market for liver cancer drugs is expected to grow steadily over the next several years, driven by increasing demand for targeted therapies and improved diagnostic techniques. Liver cancer, also known as hepatic cancer, is a type of cancer that begins in the liver's cells. It is the second most common cause of cancer-related deaths worldwide. The market for liver cancer drugs is characterized by the presence of a few major players, including Bayer, Pfizer, and Teva Pharmaceutical Industries.
Key Takeaways:
- The global liver cancer drugs market is expected to reach $1.4 billion by 2015, growing at a CAGR of 5.1% from 2007 to 2015.
- Nexavar, a targeted therapy developed by Bayer, was approved for the treatment of liver cancer in several countries, including Japan, China, and the United States.
- ThermoDox, a phase III trial conducted by Celsion, is expected to enter the market in 2011.
- Targeted therapies, such as Nexavar and Sorafenib, are gaining popularity in the treatment of liver cancer, with several pipeline drugs in clinical trials.
- Chemotherapy, surgery, and cryosurgery are also common treatments for liver cancer.
Statistics:
- Incidence of liver cancer in select countries: 2007 (table 1)
+ China: 340,000 cases
+ United States: 15,500 cases
+ Japan: 20,000 cases
- Global Nexavar sales (2007-2015) (table 2): $1.2 billion
- Worldwide ThermoDox sales: 2011-2015 (table 3): $500 million
- Pipeline drugs in liver cancer treatment (table 6):
+ 16 drugs in phase III clinical trials
+ 21 drugs in phase II clinical trials
+ 17 drugs in other clinical trial stages
Sources:
- Reportlinker.com
- PRNewswire
- Table 1: Incidence and Mortality of Liver Cancer in Select Countries: 2007
- Table 2: Global Nexavar Sales (2007-2015) (in US$ Million)
- Table 3: Worldwide ThermoDox Sales: 2011-2015 (in US$ Million)